Copyright and Licensing Considerations When Using Existing COA Scales in Clinical Trials

Source: EClinCloud. Author: eClinCloud.


The FDA defines a COA as a tool that describes or reflects how a patient feels, functions, or survives in a clinical trial, and can be a clinical outcome assessment reported by a clinician, patient, or non-clinician observer, or a performance-based assessment.
COAs include the following 4 types, among which PROs are the most widely used.
Patient-Reported Outcome
Patient-Reported Outcome (PRO)
Clinician-Reported Outcome
Clinician-Reported Outcome (ClinRO)
Observer-Reported Outcome
Observer-Reported Outcome (ObsRO)
Performance Outcome
Performance Outcome (PerfO)
PRO
A subjective response coming directly from the patient about their health condition and health-related aspects, which does not include evaluation of the patient's subjective response by a clinician or anyone else.
A PRO can be measured by self-report or interview, provided that the interviewer only records the patient's responses. Symptoms or other unobservable concepts known only to the patient (for example, pain severity or nausea) can only be measured by PRO assessments. A PRO can also assess the patient's perspective on functioning or activities (which may also be observable by others).
ClinRO
An assessment of a report of the patient's health condition performed by a healthcare professional. Most ClinRO assessments involve clinical judgment or interpretation, including observable signs, behaviors, or other disease-related phenomena. ClinRO assessments cannot directly assess symptoms known only to the patient (for example, pain intensity).
ObsRO
An assessment of a report of the patient's health condition performed by someone other than the patient or a healthcare professional, covering signs, events, or behaviors related to the patient's health condition. Typically, an ObsRO is reported by a parent, caregiver, or someone who observes the patient in daily life, and ObsROs are especially useful for patients who cannot self-report (for example, infants or individuals with cognitive impairment). ObsRO assessments do not include clinical judgment or interpretation.
PerfO
An assessment of a standardized task performed by the patient. The standardized task may be administered and evaluated by trained personnel, or completed independently by the patient. PerfOs require the patient's cooperation; these assessments include gait speed tests (for example, the Timed 25-Foot Walk test), memory tests (for example, a word recall test), or other cognitive tests (for example, the Digit Symbol Substitution Test).
Accurate clinical outcome assessment (COA) is key to the success of a clinical trial. To obtain valuable information from clinical trial patients, using an appropriate COA measurement tool is a prerequisite for obtaining accurate and reliable results. COA measurement is typically conducted using validated scales.

Scales are a measurement and assessment tool commonly used in clinical practice
and an essential instrument for assessing disease severity and supporting objective diagnosis and treatment.
Compared with other examination methods,
scales are simpler and more accurate to use,
and have therefore become
an important standard for measuring treatment effects in evidence-based medicine research.
A scale is a measurement tool jointly developed by multiple teams or disciplines (such as clinical medicine and psychology) for a specific research purpose to quantify impressions obtained through observation. It is typically administered as a standardized questionnaire and can be used in the general healthy population or in populations with a specific disease.
As a major component of clinical outcome assessment (COA), scales are undoubtedly also an essential one. Information collected through scales provides insights into specific populations, such as symptoms, overall health status, and the impact of disease and treatment on patients' quality of life.
Today, scales have become an important part of routine clinical work, helping clinicians quickly identify the root cause of a problem.
Even laboratory tests with high sensitivity and specificity cannot replace neuropsychological scale assessments, which quantify cognitive function and assist with localization and qualitative diagnosis. Neuropsychological assessment helps guide diagnostic and treatment plans, evaluate treatment efficacy, and predict disease progression, and has become an important tool in clinical practice and clinical research across departments such as neurology, neurosurgery, psychiatry, geriatrics, and rehabilitation and sports medicine.
In addition, scales help physicians conduct effective patient management and follow-up.
While scales are widely used and very important in clinical practice, using existing scales requires attention to copyright and licensing. With a wide variety of scales, varying degrees of validation, and uneven quality, selecting the appropriate version can also be difficult.
The copyright holder refuses authorization
Higher, punitive licensing fees may be charged
Delays in obtaining copyright clearance cause project delays
Unprofessional translation may also lead to:
- Disapproval by the ethics committee
- Revocation of the license by the copyright holder
- Rejection letter from regulatory authorities
- Re-commissioning of the translation
Identification / Due Diligence (1–2 weeks)
- Select the appropriate scale version and required number of copies, and confirm available scale languages
- Identify the copyright holder and costs associated with purchasing the license
Rights / Licensing (1–2 weeks)
- Contact the copyright holder to obtain authorization to use the scale
- Receive the original English version of the scale
Translation / Validation (6–8 weeks)
- Translate the scale in accordance with cross-cultural adaptation guidelines, including translation, reconciliation, back-translation, and cultural adaptation
- Deliver the final translated scale version and corresponding Certificates of Translation (COTs) to the sponsor
Execution
- Scale quality control
- Distribution of paper scales (if needed)
Working backward from copyright-holder outreach through scale translation and validation, it is best to allow at least 3 months prior to the IRB submission date.
For all of these processes and challenges,
EClinCloud
can help you resolve them.
A professional medical team interprets the protocol and determines the exact scale version;
Well-established collaborative relationships with multiple scale authors or copyright holders, with fast response times;
The service team has extensive eCOA implementation experience, with large-scale international project experience across every stage, including copyright management, scale migration, device rental and maintenance, and data analysis and reporting;
eCOA systems and processes are recognized by regulatory authorities such as the FDA, holding more than 50% of the global market share;
With a local service team in place, client communication is more convenient;
Collaborative relationships with local neurology experts (KOLs) to provide rater training and certification services.



